The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 22, 2025

Filed:

Dec. 10, 2019
Applicant:

New York University, New York, NY (US);

Inventor:

Einar M. Sigurdsson, Scarsdale, NY (US);

Assignee:

NEW YORK UNIVERSITY, New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 49/00 (2006.01); A61P 25/28 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61P 25/28 (2018.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01);
Abstract

The present invention relates to antibody-based molecules that are capable of preferentially and selectively binding to the C-terminal di-phosphorylatedSer396/Ser404 Tau peptide as well as to theSer404 Tau peptide and the non-phosphorylated Tau peptide, but does not bind to theSer396 Tau peptide. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other Tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody-based molecules of the present invention also have particular utility as prophylactic and therapeutic molecules for the treatment and/or prevention of Alzheimer's disease and related tauopathies.


Find Patent Forward Citations

Loading…